Missed Biogen's Run? What Holders Had To Believe
If you had been weighing Biogen back in October 2025, the split in analyst views was hard to ignore. For Biogen shareholders, the return over the past year was 67.2%, including dividends. That kind of payoff raises an awkward question. If you were deciding then, how much weight would you have put on cautious forecasts for shrinking revenue versus the promise of Alzheimer’s drugs and a broadening neurology pipeline?
Biogen is not the only name tied to this theme. Zero in on 34 healthcare AI stocks and compare how each one is priced.
The Two Biogen Stories Investors Had To Price In
The shares cost US$150 at the start of the period, which left you choosing between two very different stories about where Biogen might reasonably settle.
The bullish narrative pointed to a fair value of US$170, a notional price based on the idea that revenue would decline 2.1% a year while profit margins climbed toward 22.4% and a future P/E of 14.9x.
The bearish view argued for a fair value of US$115, hinging on revenue falling 5.0% annually and concerns that rising pricing pressure and generic competition could weigh heavily on Biogen’s branded portfolio.
What The Biogen Evidence Actually Tested
For Biogen, the clearest new fact was the US$5.3b Apellis deal, which added EMPAVELI and SYFOVRE to support the bullish story of a broader neurology and nephrology portfolio. Quarterly figures pulled the other way. Revenue in Q2 2026 was US$2,736m versus US$2,645.5m in Q2 2025, while net income dropped from US$634.8m to US$97.5m and net margin fell to 3.6%. The evidence cut both ways.
The original debate hinged on whether Biogen could defend profitability while funding new products and acquisitions. When judging another drug maker, investors can track whether net income and margin move in line with the growth pitch or are being traded away to buy extra pipeline.
What You Are Paying For In Biogen Today
Biogen shares are now US$251, up 67.2% over the past year, while the selected Narrative puts its Fair Value below that level based on its own model and assumptions.
The Narrative argues that today’s price assumes Biogen’s broader growth portfolio delivers durable earnings. How comfortable are you that concentrated risks in Alzheimer’s and newer immunology and nephrology assets do not upset that equation?
"The numbers imply Biogen’s share price already bakes in successful execution on its growth portfolio, pipeline readouts, and recent acquisitions, leaving limited room for disappointment if assets such as Alzheimer’s and lupus programs do not meet expectations."
One Narrative disagrees with today's price. → See where this Narrative says Biogen should trade
Which Company Could Surprise You Next?
What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.
- Company 1 - 35% below our estimate - focuses on higher margin aftermarket work and integrates acquired valve assets into existing operations.
- Company 2 - 21% below our estimate - leans into hyperscale data center builds that influence segment backlogs and operating cash generation.
- Company 3 - 24% below our estimate - ties an established software ecosystem to paid AI workloads across cloud, productivity and coding tools.
Three companies from the same screener. Open all 29 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com